AChEi Brief: References

Research Advisory Committee on Gulf War Veterans’ Illnesses (RAC-GWVI)

AChEi Brief: References

Acetylcholinesterase Inhibitor Brief: References

1.Fricker RD, Reardon E, Spektor DM, et al. A Review of the Scientific Literature as It Pertains to Gulf War Illnesses. Volume 12: Pesticide Use During the Gulf War: A Survey of Gulf War Veterans. Santa Monica, CA: RAND, MR-1018/12-OSD; 2000.

2.Golomb BA. Illness in Persian Gulf War veterans: Evidence for a causal role for acetylcholinesterase inhibitors (pyridostigmine bromide, pesticides, and nerve agent). Submitted.

3.Nisenbaum R, Barrett DH, Reyes M, Reeves WC. Deployment stressors and a chronic multisymptom illness among Gulf War veterans. J Nerv Ment Dis. 2000;188:259-66.

4.Unwin C, Blatchley N, Coker W, et al. Health of UK servicemen who served in the Persian Gulf war. Lancet. 1999;353:169-178.

5.Golomb BA. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 2: Pyridostigmine Bromide. Santa Monica, CA: RAND; 1999:385.

6.Cecchine G, Golomb BA, Hilborne LH, Spektor DM, Anthony CR. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 8: Pesticides. Santa Monica, CA: RAND; 2000:182.

7.Li L, Shou Y, Borowitz JL, Isom GE. Reactive oxygen species mediate pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and NMDA receptors. Toxicol Appl Pharmacol. 2001;177:17-25.

8.Li L, Gunasekar PG, Borowitz JL, Isom GE. Muscarinic receptor-mediated pyridostigmine-induced neuronal apoptosis. Neurotoxicology. 2000;21:541-552.

9.Pascuzzo GJ, Akaike A, Maleque MA, et al. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex I. Agonist, desensitizing, and binding properties. Mol Pharmacol. 1984;25:92-101.

10.Tandon P, Padilla S, Barone S, Pope CN, Tilson HA. Fenthion produces a persistent decrease in muscarinic receptor function in the adult rat retina. Toxicol Appl Pharmacol. 1994;125:271-280.

11.Tandon P, Willig S, Pope CN, Padilla S, Tilson HA. Dose-response study of the tissue-specific effects of fenthion on receptor function in rat CNS. Toxicologist. 1994;14:257.

12.Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. Comparison of actions of carbamate anticholinesterses on the nicotinic acetylcholine receptor. Molecular Pharmacology. 1985;27:343-348.

13.Gupta RC, Patterson GT, Dettbarn W-D. Mechanisms of toxicity and tolerance to diisopropylphosphorofluoridate at the neuromuscular junction of the rat. Toxicology and Applied Pharmacology. 1986;84:541-550.

14.Eskenazi B, Bradman A, Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ Health Perspect. 1999;107 Suppl 3:409-19.

15.Costa LG, Schwab BW, Murphy SD. Tolerance to anticholinesterase compounds in mammals. Toxicology. 1982;25:79-97.

16.Buccafusco JJ. Chronic organophosphorus exposure and cognition. 1999 Annual Report to Congress on Gulf War Veterans' Illnesses. 2000:101.

17.Lev-Lehman E, Evron T, Broide R, et al. Synaptogenesis and myopathy under acetylcholinesterase overexpression. Journal of Molecular Neuroscience. 2000;14:93-105.

18.Robinson D, McGee R. Agonist-induced regulation of neuronal nicotinic acetylcholine receptor of PC12 cells. Molecular Pharmacology. 1985;27:409-417.

19.Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. Comparison of actions of carbamate anticholinesterses on the nicotinic acetylcholine receptor. Molecular Pharmacology. 1985;27:343-348.

20.Shaw K-P, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX. The reversible cholinesterase inhibitor physostgmine has channelblocking and agonist efects on the acetylcholine receptor-ion channel complex. Molecular Pharmacology. 1985;28:527-238.

21.Anderson RJ, Chamberlain WL, Roesner M, Dacko C, Robertson DG. Decreased tetanic contracture of rat skeletal muscle induced by pyridostigmine. J Toxicol Environ Health. 1986;18:221-230.

22.Haley RW, Billecke S, La Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol. 1999;157:227-33.

23.La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos. 2001;29:566-9.

24.Mackness B, Durrington PN, Mackness MI. Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun. 2000;276:729-33.

25.Cherry N, Mackness M, Durrington P, et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet. 2002;359:763-4.

26.Cecchine G, Golomb B, Hilborne LH, Spektor DM, Anthony CR. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 8: Pesticides. Washington, DC: RAND; 2000:182.

27.Cherry N, Creed F, Silman A, et al. Health and exposures of United Kingdom Gulf war veterans. Part II: The relation of health to exposure. Occup Environ Med. 2001;58:299-306.

28.Gray GC, Reed RJ, Kaiser KS, Smith TC, Gastanaga VM. Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. Am J Epidemiol. 2002;155:1033-44.

29.Haley RW, Kurt TL. Self-reported exposure to neurotoxic chemical combinations in the Gulf War. A cross-sectional epidemiologic study. Jama. 1997;277:231-7.

30.Kang HK, Mahan CM, Lee KY, Magee CA, Murphy FM. Illnesses among United States veterans of the Gulf War: a population-based survey of 30,000 veterans. J Occup Environ Med. 2000;42:491-501.

31.Kang H, Mahan CM, Lee KY, et al. Evidence for a deployment-related Gulf War syndrome by factor analysis. : Arch Environ Health; 2002:58.

32.Kroenke K, Koslowe P, Roy M. Symptoms in 18,495 Persian Gulf War veterans. Latency of onset and lack of association with self-reported exposures. Journal of Occupational and Environmental Medicine. 1998;40:520-8.

33.Proctor SP, Harley R, Wolfe J, Heeren T, White RF. Health-related quality of life in Persian Gulf War Veterans. Mil Med. 2001;166:510-9.

34.Reid S, Hotopf M, Hull L, Ismail K, Unwin C, Wessely S. Multiple chemical sensitivity and chronic fatigue syndrome in British Gulf War veterans. Am J Epidemiol. 2001;153:604-9.

35.Schumm WR, Reppert EJ, Jurich AP, et al. Pyridostigmine bromide and the long-term subjective health status of a sample of female reserve component Gulf War veterans: a brief report. Psychol Rep. 2001;88:306-8.

36.Schumm WR, Reppert EJ, Jurich AP, et al. Pyridostigmine bromide and the long-term subjective health status of a sample of over 700 male Reserve Component Gulf War era veterans. Psychol Rep. 2002;90:707-21.

37.White RF, Proctor SP, Heeren T, et al. Neuropsychological function in Gulf War veterans: relationships to self-reported toxicant exposures. Am J Ind Med. 2001;40:42-54.

38.McCauley LA, Rischitelli G, Lambert WE, Lasarev M, Sticker DL, Spencer PS. Symptoms of Gulf War veterans possibly exposed to organophosphate chemical warfare agents at Khamisiyah, Iraq. Int J Occup Environ Health. 2001;7:79-89.

39.McCauley L, Lasarev M, Sticker D, Rischitelli D, Spencer P. Illness experience of Gulf War veterans possibly exposed to chemical warfare agents. Am J Prev Med. 2002;23:200.

40.Gray G, Coate B, Anderson C, et al. The postwar hospitalization experience of US veterans of the Persian Gulf War. New Engl J Med. 1996;335:1505-1513.

41.Gray GC, Smith TC, Kang HK, Knoke JD. Are Gulf War veterans suffering war-related illnesses? Federal and civilian hospitalizations examined, June 1991 to December 1994. Am J Epidemiol. 2000;151:63-71.

42.Kaiser KS. Pyridostigmine bromide intake during the Persian Gulf War is not associated with postwar handgrip strength. Mil Med. 2000;165:165-8.

43.Golomb BA. Chapter 14. Chronic Effect. In: A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 2: Pyridostigmine Bromide. Santa Monica, CA: RAND; 1999:385.

44.Lotti M. Low-level exposures to organophosphorus esters and peripheral nerve function. Muscle Nerve. 2002;25:492-504.

45.Ray DE. Chronic effects of low level exposure to anticholinesterases. Toxicology Letters. 1998;95:26.

46.Glass-Marmor L, Beitner R. Effects of carbamylcholine and pyridostigmine on mitochondrial-bound hexokinase in skeletal muscle and heart. Biochem Mol Med. 1996;57:67-70.

47.Francesconi R, Hubbard R, Mager M. Effects of pyridostigmine on ability of rats to work in the heat. J Appl Physiol. 1984;56:891-5.

48.Babu SR, Buckenmeyer P, Knowlton RG, Somani SM. Effect of physostigmine on plasma lactate and pyruvate in untrained/trained rats. Pharmacol Biochem Behav. 1992;42:67-73.

49.Buckenmeyer PJ, Babu SR, Knowlton RG, Somani SM. Effect of concurrent exercise and physostigmine on lactate and pyruvate in plasma, muscle, and brain tissue of rats. Pharmacol Biochem Behav. 1994;47:779-88.

50.De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. British Journal of Clinical Pharmacology. 1996;42:333-7.

51.Chariot P, Monnet I, Mouchet M, et al. Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum. 1994;37:583-6.

52.Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cellular and Molecular Biology. 1997;43:741-9.

53.Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. Journal of the Neurological Sciences. 1998;156:41-6.

54.Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. European Neurology. 1997;37:212-8.

55.Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997;48:1238-43.

56.Fosslien E. Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci. 2001;31:25-67.

57.Alleva R, Tomasetti M, Andera L, et al. Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Lett. 2001;503:46-50.

58.Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001;57:515-8.

59.Fernandez-Ayala DJ, Martin SF, Barroso MP, et al. Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid Redox Signal. 2000;2:263-75.

60.Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann N Y Acad Sci. 1999;887:31-47.

61.Mosca L, Marcellini S, Perluigi M, et al. Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol. 2002;63:1305-14.

62.Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379-82.

63.Tedeschi D, Lombardi V, Mancuso M, et al. Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: new diagnostic approaches for new rationale therapeutics. Neurol Sci. 2000;21:S979-80.

64.Takusa Y, Yamaguchi S. [Myopathies with miscellaneous disorders related to mitochondrial fatty acid oxidation: defective synthesis of ketone body, long-chain fatty acid transport defect, and muscular coenzyme Q10 deficiency]. Ryoikibetsu Shokogun Shirizu. 2001:90-4.

65.Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta. 1995;1271:281-6.

66.Shimomura Y, Suzuki M, Sugiyama S, Hanaki Y, Ozawa T. Protective effect of coenzyme Q10 on exercise-induced muscular injury. Biochem Biophys Res Commun. 1991;176:349-55.

67.Elble R, Giacobini E, Higgins C. Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging. 1989;10:45-50.

68.Berrettini WH, Garrick NA, Nurnberger JI, Jr., et al. Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y. Biol Psychiatry. 1989;26:623-30.

69.Davis KL, Faull KF, Hollister LE, Barchas JD, Berger PA. Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion. Psychopharmacology (Berl). 1981;72:155-60.

70.Kaye JA, May C, Atack JR, et al. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Ann Neurol. 1988;24:647-50.

71.Jolkkonen J, Soininen H, Halonen T, et al. Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. J Neurol Neurosurg Psychiatry. 1986;49:1374-7.

72.Gomez S, Davous P, Rondot P, Faivre-Bauman A, Valade D, Puymirat J. Somatostatin-like immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of the Alzheimer type. Psychoneuroendocrinology. 1986;11:69-73.

73.Hartikainen P, Reinikainen KJ, Soininen H, Sirvio J, Soikkeli R, Riekkinen PJ. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm Park Dis Dement Sect. 1992;4:53-68.

74.Davis KL, Hollister LE, Goodwin FK, Gordon EK. Neurotransmitter metabolites in the cerebrospinal fluid of man following physostigmine. Life Sci. 1977;21:933-6.

75.Popovic M, Popovic N, Jovanova-Nesic K, et al. Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease. Int J Neurosci. 1997;90:87-97.

76.Peskind ER, Wingerson D, Pascualy M, et al. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Biol Psychiatry. 1995;38:532-8.

77.degli Uberti EC, Bondanelli M, Margutti A, et al. Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide. Neuroendocrinology. 1996;64:398-404.

78.Araki S, Shibasaki H. [Variations in serum amylase responding to the neostigmine test in amyotrophic lateral sclerosis]. Igaku To Seibutsugaku. 1966;73:233-9.

79.Gowen GF. A second look at the neostigmine morphine test. Am Surg. 1989;55:640-4.

80.Bell IR, Patarca R, Baldwin CM, Klimas NG, Schwartz GE, Hardin EE. Serum neopterin and somatization in women with chemical intolerance, depressives, and normals. Neuropsychobiology. 1998;38:13-8.

81.Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. Mech Ageing Dev. 2001;122:2057-62.

82.Appleyard ME, Smith AD, Berman P, et al. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain. 1987;110 ( Pt 5):1309-22.

83.Appleyard ME, McDonald B. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1992;55:1074-8.

84.Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. Am Surg. 2001;67:265-8; discussion 268-9.

85.Adams SB, MacHarg MA. Neostigmine methylsulfate delays gastric emptying of particulate markers in horses. Am J Vet Res. 1985;46:2498-9.

86.Amaro R, Rogers AI. Neostigmine infusion: new standard of care for acute colonic pseudo-obstruction? Am J Gastroenterol. 2000;95:304-5.

87.Alitalo I, Hietala A. Effects of atropine, isoprenaline, neostigmine and practocol on cardiac arrhythmias induced by potassium in anesthetized dogs. Nord Vet Med. 1977;29:498-501.

88.Anzueto A, deLemos RA, Seidenfeld J, et al. Acute inhalation toxicity of soman and sarin in baboons. Fundam Appl Toxicol. 1990;14:676-87.

89.Haley RW, Vongpatanasin W, Wolfe GI, et al. Abnormal control of heart rate variability in veterans with Gulf War Syndrome. Submitted for publication.

90.Ally A, Wilson LB, Nobrega AC, Mitchell JH. Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats. Brain Res. 1995;677:268-76.

91.Ally A, Hand GA, Mitchell JH. Central injection of physostigmine attenuates exercise-induced pressor response in conscious cats. Am J Physiol. 1997;273:R393-9.

92.Jancin B. Pyridostigmine reduced orthostatic intolerance. Internal Medicine News. 2002;June 15:32.

93.Park KH, Long JP, Cannon JG. Reversal of antihypertensive agent-induced postural hypotension with physostigmine. Arch Int Pharmacodyn Ther. 1991;311:155-65.

94.Hata S, Kunida H, Oyama Y. [Antihypertensive effects of coenzyme Q10 in essential hypertension--in relation to the renin-aldosterone system]. Horumon To Rinsho. 1977;25:1019-23.

95.Aoyagi M, Meyer JS, Deshmukh VD, et al. Central cholinergic control of cerebral blood flow in the baboon. Effect of cholinesterase inhibition with neostigmine on autoregulation and CO2 responsiveness. J Neurosurg. 1975;43:689-705.

96.Eneroth-Grimfors E, Lindblad LE, Westgren M, Ihrman-Sandahl C, Bevegard S. Noninvasive test of microvascular endothelial function in normal and hypertensive pregnancies. Br J Obstet Gynaecol. 1993;100:469-71.

97.Arora S, Veves A, Caballaro AE, Smakowski P, LoGerfo FW. Estrogen improves endothelial function. J Vasc Surg. 1998;27:1141-6; discussion 1147.

98.Kubli S, Waeber B, Dalle-Ave A, Feihl F. Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol. 2000;36:640-8.

99.Williams MR, Westerman RA, Kingwell BA, et al. Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab. 2001;86:5389-95.

100.Newton DJ, Khan F, Belch JJ. Assessment of microvascular endothelial function in human skin. Clin Sci (Lond). 2001;101:567-72.

101.Elherik K, Khan F, McLaren M, Kennedy G, Belch JJ. Circadian variation in vascular tone and endothelial cell function in normal males. Clin Sci (Lond). 2002;102:547-52.

102.Lim SC, Caballero AE, Arora S, et al. The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab. 1999;84:4159-64.

103.Wirtschafter JD, Volk CR, Sawchuk RJ. Transaqueous diffusion of acetylcholine to denervated iris sphincter muscle: a mechanism for the tonic pupil syndrome (Adie syndrome). Ann Neurol. 1978;4:1-5.

104.Fountoulakis K, Fotiou F, Iacovides A, et al. Changes in pupil reaction to light in melancholic patients. Int J Psychophysiol. 1999;31:121-8.

105.Elliott A, Carter C. Pupil size after extracapsular cataract extraction and posterior chamber lens implantation: a prospective randomized trial of epinephrine and acetylcholine. Ophthalmic Surg. 1989;20:591-4.

106.Suzuki R, Kobayashi S, Yoshino H. [The inhibitory cholinergic innervation of the dilator on the movement of the pupil]. Nippon Ganka Gakkai Zasshi. 1984;88:1555-7.

107.Naito M. [The autonomic nervous system and eyes: the role of the sympathetic nerve on extra-ocular muscle and pupil]. Nippon Ganka Gakkai Zasshi. 1971;75:988-95.

108.Pohjanpelto P. [Carbachol in cataract surgery used for constriction of the pupil]. Duodecim. 1969;85:1504-7.

109.Cook JE, Kolka MA, Wenger CB. Chronic pyridostigmine bromide administration: side effects among soldiers working in a desert environment. Mil Med. 1992;157:250-4.

110.Borland RG, Brennan DH, Nicholson AN, Smith PA. Studies on the possible central and peripheral effects in man of a cholinesterase inhibitor (pyridostigmine). Hum Toxicol. 1985;4:293-300.

111.Goel A, Joseph S, Dutta TK. Organophosphate poisoning: predicting the need for ventilatory support. J Assoc Physicians India. 1998;46:786-90.

112.Kay CD, Morrison JD. The effects of ingestion of 60 mg pyridostigmine bromide on contrast sensitivity in man. Hum Toxicol. 1988;7:347-52.

113.Loupe DN, Newman NJ, Green RC, et al. Pupillary response to tropicamide in patients with Alzheimer disease. Ophthalmology. 1996;103:495-503.

114.Macic I, Maksimovic M, Erdeljan D, Stojadinovic L. [Antagonism of miosis induced by sarin and VX in rabbits]. Vojnosanit Pregl. 1986;43:103-8.

115.Nozaki H, Hori S, Shinozawa Y, et al. Secondary exposure of medical staff to sarin vapor in the emergency room. Intensive Care Med. 1995;21:1032-5.

116.Nozaki H, Hori S, Shinozawa Y, et al. Relationship between pupil size and acetylcholinesterase activity in patients exposed to sarin vapor. Intensive Care Med. 1997;23:1005-7.

117.Rengstorff RH. Accidental exposure to sarin: vision effects. Arch Toxicol. 1985;56:201-3.

118.Sidell FR, Groff WA. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol. 1974;27:241-52.

119.Wiley RW, Kotulak JC, Behar I. The effects of pyridostigmine bromide on visual performance. Aviat Space Environ Med. 1992;63:1054-9.

120.Schneider R. A test for the assessment of the duration of the action of neostigmine and of the relative potencies of various anticholinesterases using the pupil of the mouse. J Pharm Pharmacol. 1970;22:298-301.

121.Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med. 1998;16:505-7.

122.Crowell EB, Jr., Ketchum JS. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther. 1967;8:409-14.

123.Wilhelm B, Wilhelm H, Streicher P, Ludtke H, Adler M. [Pupillography as an objective attention test]. Wien Med Wochenschr. 1996;146:387-9.

124.Wilhelm B, Wilhelm H, Ludtke H, Adler M, Streicher P. [Pupillography for objective vigilance assessment. Methodological problems and possible solutions]. Ophthalmologe. 1996;93:446-50.

125.Morad Y, Lemberg H, Yofe N, Dagan Y. Pupillography as an objective indicator of fatigue. Curr Eye Res. 2000;21:535-42.

126.Danker-Hopfe H, Kraemer S, Dorn H, Schmidt A, Ehlert I, Herrmann WM. Time-of-day variations in different measures of sleepiness (MSLT, pupillography, and SSS) and their interrelations. Psychophysiology. 2001;38:828-35.

127.Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2001:CD001499.

128.Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999;52:1146-52.

129.van Dyck CH, Newhouse P, Falk WE, Mattes JA. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. Arch Gen Psychiatry. 2000;57:157-64.

130.Memory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med. 1983;308:720-1.

131.Aigner TG, Mishkin M. The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol. 1986;45:81-7.

132.Aigner TG, Mitchell SJ, Aggleton JP, et al. Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology (Berl). 1987;92:292-300.

133.Alagiakrishnan K, Wong W, Blanchette PL. Use of donepezil in elderly patients with Alzheimer's disease--a Hawaii based study. Hawaii Med J. 2000;59:57-9.

134.Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord. 2001;12:22-32.

135.Arsland D, Laake K. [Should Alzheimer disease be treated with tacrine? Review of the literature]. Tidsskr Nor Laegeforen. 1996;116:2791-4.

136.Arendt T, Schugens MM, Bigl V. The cholinergic system and memory: amelioration of ethanol-induced memory deficiency by physostigmine in rat. Acta Neurobiol Exp (Warsz). 1990;50:251-61.

137.Ashford JW, Soldinger S, Schaeffer J, Cochran L, Jarvik LF. Physostigmine and its effect on six patients with dementia. Am J Psychiatry. 1981;138:829-30.

138.Asthana S, Greig NH, Hegedus L, et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther. 1995;58:299-309.

139.Lacey SC, Robinson KM, Umile E, et al. Evaluation of working memory in Persian Gulf War veterans with chronic fatigue [abstract]. Proceedings of the Conference on Federally Sponsored Gulf War Veteransí Illnesses Research, Pentagon City, Jun 1999, 133.134. 1999.

140.Leclercq M, Couillet J, Azouvi P, et al. Dual task performance after severe diffuse traumatic brain injury or vascular prefrontal damage. J Clin Exp Neuropsychol. 2000;22:339-50.

141.Overstreet DH, Miller CS, Janowsky DS, Russell RW. Potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. Toxicology. 1996;111:119-34.

142.Servatius RJ, Ottenweller JE, Beldowicz D, Guo W, Zhu G, Natelson BH. Persistently exaggerated startle responses in rats treated with pyridostigmine bromide. J Pharmacol Exp Ther. 1998;287:1020-8.

143.Janowsky DS, el-Yousef K, Davis JM, Sekerke HJ. Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry. 1973;28:542-7.

144.Janowsky D, Risch C, Parker D, Huey L, Judd L. Increased vulnerability to cholinergic stimulation in affective disorder patients. Psychopharmacol Bull. 1980;16:29-31.

145.Janowsky DS, Risch SC, Judd LL, Huey LY, Parker D. Cholinergic supersensitivity in affect disorder patients: Behavioral and neuroendocrine observations. Psychopharmacol Bull. 1981;17:129-132.

146.Janowsky D, Risch C, Gillin J. Adrenergic-cholinergic balance and the treatment of affective disorders. Prog Neuropsychopharmacol Biol Psychiatry. 1983;7:297-307.

147.Janowsky D, Risch C. Cholinomimetic and anti cholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders adn stress. Drug Dev Res. 1984.

148.Bannon AW, Gunther KL, Decker MW. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (+/-)-epibatidine. Pharmacol Biochem Behav. 1995;51:693-698.

149.Avlonitou E, Elizondo R. Effects of atropine and pyridostigmine in heat-stressed patas monkeys. Aviat Space Environ Med. 1988;59:544-8.

150.Barar FS, Madan BR. Tremorine-oxotremorine-induced tremor, hypothermia and analgesia, and physostigmine toxicity, in mice after pretreatment with beta-adrenoceptor antagonists. J Pharm Pharmacol. 1976;28:286-9.

151.Clement JG. Variability of sarin-induced hypothermia in mice: investigation into incidence and mechanism. Biochem Pharmacol. 1991;42:1316-8.

152.Francesconi R, Hubbard R, Matthew C, Leva N, Young J, Pease V. Oral pyridostigmine administration in rats: effects on thermoregulation, clinical chemistry, and performance in the heat. Pharmacol Biochem Behav. 1986;25:1071-5.

153.Gordon CJ. 24-hour control of body temperature in the rat: II. Diisopropyl fluorophosphate-induced hypothermia and hyperthermia. Pharmacol Biochem Behav. 1994;49:747-754.

154.Epstein Y, Seidman DS, Moran D, Arnon R, Arad M, Varssano D. Heat-exercise performance of pyridostigmine-treated subjects wearing chemical protective clothing. Aviat Space Environ Med. 1990;61:310-3.

155.Epstein Y, Arnon R, Moran D, Seidman DS, Danon Y. Effect of pyridostigmine on the exercise-heat response of man. Eur J Appl Physiol Occup Physiol. 1990;61:128-32.

156.Kassa J, Koupilova M, Herink J, Vachek J. The long-term influence of low-level sarin exposure on behavioral and neurophysiological functions in rats. Acta Medica (Hradec Kralove). 2001;44:21-7.

157.Kolka MA, Stephenson LA. Human temperature regulation during exercise after oral pyridostigmine administration. Aviat Space Environ Med. 1990;61:220-4.

158.Lin MT, Wang HC, Chandra A. The effects on thermoregulation of intracerebroventricular injections of acetylcholine, pilocarpine, physostigmine, atropine and hemicholinium in the rat. Neuropharmacology. 1980;19:561-5.

159.Matthew CB, Hubbard RW, Francesconi RP. Atropine, diazepam, and physostigmine: thermoregulatory effects in the heat-stressed rat. Life Sci. 1989;44:1921-7.

160.Matthew CB, Francesconi RP, Hubbard RW. Physostigmine: dose-response effects on endurance and thermoregulation during exercise. Life Sci. 1992;50:39-44.

161.Maickel RP, Kinney DR, Ryker DL, Nichols MB. Antagonism of physostigmine induced hypothermia and neuroendocrine changes following exposure to different environmental temperatures. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:873-84.

162.Monda M, Viggiano A, De Luca V. Administration of muscimol into the posterior hypothalamus reduces hyperthermia induced by hippocampal neostigmine injection. Brain Res. 2000;887:344-9.

163.Prusaczyk WK, Sawka MN. Effects of pyridostigmine bromide on human thermoregulation during cold water immersion. J Appl Physiol. 1991;71:432-7.

164.Roberts DE, Sawka MN, Young AJ, Freund BJ. Pyridostigmine bromide does not alter thermoregulation during exercise in cold air. Can J Physiol Pharmacol. 1994;72:788-93.

165.Sharkawi M. Morphine hyperthermia in the rat: its attenuation by physostigmine. Br J Pharmacol. 1972;44:544-8.

166.Stephenson LA, Kolka MA. Acetylcholinesterase inhibitor, pyridostigmine bromide, reduces skin blood flow in humans. Am J Physiol. 1990;258:R951-7.

167.Wenger CB, Latzka WA. Effects of pyridostigmine bromide on physiological responses to heat, exercise, and hypohydration. Aviat Space Environ Med. 1992;63:37-45.

168.Wenger B, Quigley MD, Kolka MA. Seven-day pyridostigmine administration and thermoregulation during rest and exercise in dry heat. Aviat Space Environ Med. 1993;64:905-11.

169.Billet S, Cant NB, Hall WC. Cholinergic projections to the visual thalamus and superior colliculus. Brain Res. 1999;847:121-3.

170.Lee PH, Schmidt M, Hall WC. Excitatory and inhibitory circuitry in the superficial gray layer of the superior colliculus. J Neurosci. 2001;21:8145-53.

171.Aizawa H, Kobayashi Y, Yamamoto M, Isa T. Injection of nicotine into the superior colliculus facilitates occurrence of express saccades in monkeys. J Neurophysiol. 1999;82:1642-6.

172.Binns KE. The synaptic pharmacology underlying sensory processing in the superior colliculus. Prog Neurobiol. 1999;59:129-59.

173.Wichmann T, Illing RB, Starke K. Evidence for a neurotransmitter function of acetylcholine in rabbit superior colliculus. Neuroscience. 1987;23:991-1000.

174.Beninato M, Spencer RF. A cholinergic projection to the rat superior colliculus demonstrated by retrograde transport of horseradish peroxidase and choline acetyltransferase immunohistochemistry. J Comp Neurol. 1986;253:525-38.

175.Weldon DA, Calabrese LC, Nicklaus KJ. Rotational behavior following cholinergic stimulation of the superior colliculus in rats. Pharmacol Biochem Behav. 1983;19:813-20.

176.Pazdernik TL, Cross RS, Mewes K, Samson F, Nelson SR. Superior colliculus activation by retinal nicotinic ganglion cells: a 2-deoxyglucose study. Brain Res. 1982;243:197-200.

177.Kasser RJ, Cheney PD. DFP action on rat superior colliculus: localization and role of cholinergic receptors. Neurotoxicology. 1987;8:607-22.

178.Kang HK, Bullman TA. Mortality among US veterans of the Persian Gulf War: 7-year follow-up. Am J Epidemiol. 2001;154:399-405.

179.Kang HK, Bullman TA. Mortality among U.S. veterans of the Persian Gulf War [see comments]. N Engl J Med. 1996;335:1498-504.

180.Bell NS, Amoroso PJ, Wegman DH, Senier L. Proposed explanations for excess injury among veterans of the Persian Gulf War and a call for greater attention from policymakers and researchers. Inj Prev. 2001;7:4-9.

181.Haley RW, Marshall WW, McDonald GG, Daugherty MA, Petty F, Fleckenstein JL. Brain abnormalities in Gulf War syndrome: Evaluation with 1H MR spectroscopy. Radiology. 2000;215:807-817.

182.Mayberg HS. Clinical correlates of PET- and SPECT-identified defects in dementia. Journal of Clinical Psychiatry. 1994;55:12-21.

183.Eustache F, Desgranges B, Giffard B, de la Sayette V, Baron J-C. Entorhinal cortex disruption causes memory deficit in early Alzheimer's disease as shown by PET. Neuroreport. 2001;12:683-685.

184.Tani Y, Ishihara T, Kanai T, et al. 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP, SUN 0588) acts on the brain muscarinic and nicotinic cholinergic receptors as evaluated by positron emission tomography (PET) in rhesus monkey. Adv Exp Med Biol. 1993;338:331-4.

185.Nordberg A, Amberla K, Shigeta M, et al. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord. 1998;12:228-37.

186.Ding YS, Gatley SJ, Fowler JS, et al. Mapping nicotinic acetylcholine receptors with PET. Synapse. 1996;24:403-7.

187.Chefer SI, Horti AG, Koren AO, et al. 2-[18F]F-A-85380: a PET radioligand for alpha4beta2 nicotinic acetylcholine receptors. Neuroreport. 1999;10:2715-21.

188.Dolci L, Dolle F, Valette H, et al. Synthesis of a fluorine-18 labeled derivative of epibatidine for in vivo nicotinic acetylcholine receptor PET imaging. Bioorg Med Chem. 1999;7:467-79.

189.Horti A, Scheffel U, Stathis M, et al. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J Nucl Med. 1997;38:1260-5.

190.Ding Y, Liu N, Wang T, et al. Synthesis and evaluation of 6-[(18)F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine as a PET tracer for nicotinic acetylcholine receptors. Nucl Med Biol. 2000;27:381-9.

191.Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry. 1998;65:155-63.

192.Mentis MJ, Sunderland T, Lai J, et al. Muscarinic versus nicotinic modulation of a visual task. a pet study using drug probes. Neuropsychopharmacology. 2001;25:555-64.

193.Furey ML, Pietrini P, Haxby JV, et al. Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. Proc Natl Acad Sci U S A. 1997;94:6512-6.

194.Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999;52:691-9.

195.Shinotoh H, Namba H, Fukushi K, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol. 2000;48:194-200.

196.Meltzer CC, Smith G, Dekosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407-430.

197.Price JC, Kelley DE, Ryan CM, et al. PET imaging of serotonin-1A receptors in type 2 diabetes: Evidence of increased binding. Journal of Nuclear Medicine. 2001;42:18P.

198.Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120:2207-2217.

199.Schroeder U, Kuehler A, Haslinger B, et al. Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: A PET study. Brain. 2002;125:1995-2004.

200.de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-(18F)fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proceedings of the National Academy of Sciences of the United States of America. 2001;98:10966-10971.

201.Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: The role of the prefrontal cortex revealed by PET. Brain. 2002;125:584-594.

202.Arakawa K, Peachey NS, Celesia G, Rubboli G. Component-specific effects of physostigmine on the cat visual evoked potential. Exp Brain Res. 1993;95:271-6.

203.Thierry G, Doyon B, Demonet J-F. ERP mapping in phonological and lexical semantic monitoring tasks: A study complementing previous PET results. NeuroImage. 1998;8:391-408.

204.Abdullaev YG, Posner MI. Event-related brain potential imaging of semantic encoding during processing single words. NeuroImage. 1998;7:1-13.

205.Gazzard MF, Thomas DP. A comparative study of central visual field changes induced by sarin vapour and physostigmine eye drops. Exp Eye Res. 1975;20:15-21.

206.Alderdice MT. Physostigmine, but not neostigmine, inhibits acetylcholine release. Brain Res. 1979;178:596-9.

207.Alderdice MT. Further comparison of the effects of physostigmine and neostigmine on frog neuromuscular transmission. Clin Exp Pharmacol Physiol. 1982;9:35-43.

208.Abdel-Rahman A, Shetty A, Abou-Donia M. Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of gulf-war syndrome. Neurobiol Dis. 2002;10:306.

209.Abdel-Rahman A, Shetty AK, Abou-Donia MB. Acute exposure to sarin increases blood brain barrier permeability and induces neuropathological changes in the rat brain: dose-response relationships. Neuroscience. 2002;113:721-41.

210.Li L, Gunasekar PG, Borowitz JL, Isom GE. Muscarinic receptor-mediated pyridostigmine-induced neuronal apoptosis. Neurotoxicology. 2000;21:541-52.

211.Alberts P, Ogren VR. Sarin and soman depress [3H]acetylcholine secretion in guinea-pig ileum myenteric plexus. Acta Physiol Scand. 1985;125:347-8.

212.Arroyo G, Aldea M, Fuentealba J, Garc a AG. [Nicotinic Receptor, galantamine and Alzheimer disease]. Rev Neurol. 2002;34:1057-65.

213.Akaike A, Ikeda SR, Brookes N, Pascuzzo GJ, Rickett DL, Albuquerque EX. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. II. Patch clamp studies. Mol Pharmacol. 1984;25:102-12.

214.Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms. Neurochem Int. 1992;21:381-96.

215.Antonelli T, Beani L, Bianchi C, Pedata F, Pepeu G. Changes in synaptosomal high affinity choline uptake following electrical stimulation of guinea-pig cortical slices: effect of atropine and physostigmine. Br J Pharmacol. 1981;74:525-31.

216.Abdel-Rahman A, Shetty AK, Abou-Donia MB. Subchronic dermal application of N,N-diethyl m-toluamide (DEET) and permethrin to adult rats, alone or in combination, causes diffuse neuronal cell death and cytoskeletal abnormalities in the cerebral cortex and the hippocampus, and Purkinje neuron loss in the cerebellum. Exp Neurol. 2001;172:153-71.

217.Aizenman E, Bierkamper GG, Stanley EF. Botulinum toxin prevents stimulus-induced backfiring produced by neostigmine in the mouse phrenic nerve-diaphragm. J Physiol. 1986;372:395-404.

218.Amaki Y, Kobayashi K, Kaneko M. [The effect of neostigmine and edrophonium on the MEPP frequency]. Masui. 1989;38:760-6.

219.Anderson RJ, Chamberlain WL, Roesner M, Dacko C, Robertson DG. Decreased tetanic contracture of rat skeletal muscle induced by pyridostigmine. J Toxicol Environ Health. 1986;18:221-30.

220.Anderson RJ. Effect of pyridostigmine on tetanic contracture of innervated and denervated rat skeletal muscle. Neurotoxicology. 1987;8:553-60.

221.Anderson RJ, Chamberlain WL. Pyridostigmine-induced decrement in skeletal muscle contracture is not augmented by soman. Neurotoxicology. 1988;9:89-96.

222.Damodaran TV, Bilska MA, Rahman AA, Abou-Doni MB. Sarin causes early differential alteration and persistent overexpression in mRNAs coding for glial fibrillary acidic protein (GFAP) and vimentin genes in the central nervous system of rats. Neurochem Res. 2002;27:407-15.

223.Glass-Marmor L, Chen-Zion M, Beitner R. Effects of carbamylcholine and pyridostigmine on cytoskeleton-bound and cytosolic phosphofructokinase and ATP levels in different rat tissues. Gen Pharmacol. 1996;27:1241-6.

224.Somani SM, Kutty RK, Krishna G. Eseroline, a metabolite of physostigmine, induces neuronal cell death. Toxicol Appl Pharmacol. 1990;106:28-37.

225.Spencer PS, McCauley LA, Lapidus JA, Lasarev M, Joos SK, Storzbach D. Self-reported exposures and their association with unexplained illness in a population-based case-control study of Gulf War veterans. J Occup Environ Med. 2001;43:1041-56.

226.Abu-Qare AW, Abou-Donia MB. Combined exposure to sarin and pyridostigmine bromide increased levels of rat urinary 3-nitrotyrosine and 8-hydroxy-2'-deoxyguanosine, biomarkers of oxidative stress. Toxicol Lett. 2001;123:51-8.

227.Abu-Qare AW, Suliman HB, Abou-Donia MB. Induction of urinary excretion of 3-nitrotyrosine, a marker of oxidative stress, following administration of pyridostigmine bromide, DEET (N,N-diethyl-m-toluamide) and permethrin, alone and in combination in rats. Toxicol Lett. 2001;121:127-34.

228.Artru AA, Michenfelder JD. A re-examination of physostigmine-induced cerebral protection in the hypoxic mouse. A critical assessment of the model. Stroke. 1980;11:197-9.

229.Andjelkovic DS, Terzic MR. The effects of physostigmine on the oxygen uptake in rat brain tissue. Experientia. 1979;35:372-3.

230.Rupreht J, Schneck HJ, Dworacek B. [Physostigmine--recent pharmacologic data and their significance for practical use]. Anaesthesiol Reanim. 1989;14:235-41.

231.Bradley RJ, Sterz R, Peper K. Agonist and inhibitory effects of pyridostigmine at the neuromuscular junction. Brain Res. 1986;376:199-203.

232.Zheng JQ, He XP, Yang AZ, Liu CG. Neostigmine competitively inhibited nicotinic acetylcholine receptors in sympathetic neurons. Life Sci. 1998;62:1171-8.

233.Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol Pharmacol. 1985;28:527-38.

234.Zheng JQ, He XP, Yang AZ, Liu CG. Physostigmine blocked nicotinic acetylcholine receptors in rat sympathetic ganglion neurons. Zhongguo Yao Li Xue Bao. 1997;18:508-11.

235.Navratil J, Sklenovsky A, Camela Z, Rypka M. The labilizing and stabilizing effect of physostigmine on CNS. Acta Univ Palacki Olomuc Fac Med. 1990;126:39-44.

236.Navratil J, Sklenovsky A, Chmela Z, Rypka M. Increase of nonesterified fatty acids in CNS after physostigmine application. Homeost Health Dis. 1991;33:172-3.

237.Tapia R. Release and uptake of glutamate as related to excitotoxicity. Rev Bras Biol. 1996;56 Su 1 Pt 1:165-74.

238.Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000;6:67-70.

239.Chen Q, Veenman CL, Reiner A. Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience. 1996;73:715-31.

240.Paschen W. Glutamate excitotoxicity in transient global cerebral ischemia. Acta Neurobiol Exp (Warsz). 1996;56:313-22.

241.Zhang J, Price JO, Graham DG, Montine TJ. Secondary excitotoxicity contributes to dopamine-induced apoptosis of dopaminergic neuronal cultures. Biochem Biophys Res Commun. 1998;248:812-6.

242.Hugon J, Vallat JM, Dumas M. [Role of glutamate and excitotoxicity in neurologic diseases]. Rev Neurol (Paris). 1996;152:239-48.

243.Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol. 1997;244 Suppl 2:S3-14.

244.US links motor neurone disease with Gulf War service. BMJ. 2002;324:65.

245.Nguimfack Mbodie PC. [Do the glutamate excitotoxicity theory and potential free radicals implication in schizophrenia aetiopathogenesis provide a new enlightenment to links between: genome, environment and biology in the determinism of that disorder?]. Encephale. 2002;28:147-53.

246.Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999;81:163-221.

247.Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 1998;44:S175-88.

248.Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol. 1998;44:S110-4.

249.Zhang J, Price JO, Graham DG, Montine TJ. Secondary excitotoxicity contributes to dopamine-induced apoptosis of dopaminergic neuronal cultures. Biochem Biophys Res Commun. 1998;248:812-6.

250.Hugon J, Vallat JM, Dumas M. [Role of glutamate and excitotoxicity in neurologic diseases]. Rev Neurol (Paris). 1996;152:239-48.

251.Olney JW, Zorumski CF, Stewart GR, Price MT, Wang GJ, Labruyere J. Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases. Exp Neurol. 1990;108:269-72.

252.Greene JG, Greenamyre JT. Bioenergetics and glutamate excitotoxicity. Prog Neurobiol. 1996;48:613-34.

253.Tymianski M, Sattler R, Zabramski JM, Spetzler RF. Characterization of neuroprotection from excitotoxicity by moderate and profound hypothermia in cultured cortical neurons unmasks a temperature-insensitive component of glutamate neurotoxicity. J Cereb Blood Flow Metab. 1998;18:848-67.

254.Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem. 1996;67:2282-91.

255.Nicholls DG, Budd SL. Mitochondria and neuronal glutamate excitotoxicity. Biochim Biophys Acta. 1998;1366:97-112.

256.Castilho RF, Ward MW, Nicholls DG. Oxidative stress, mitochondrial function, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem. 1999;72:1394-401.

257.Schubert D, Piasecki D. Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J Neurosci. 2001;21:7455-62.

258.Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res. 1994;655:251-4.

259.Tombaugh GC, Yang SH, Swanson RA, Sapolsky RM. Glucocorticoids exacerbate hypoxic and hypoglycemic hippocampal injury in vitro: biochemical correlates and a role for astrocytes. J Neurochem. 1992;59:137-46.

260.Suchecki D, Tiba PA, Tufik S. Paradoxical sleep deprivation facilitates subsequent corticosterone response to a mild stressor in rats. Neurosci Lett. 2002;320:45-8.

261.Hairston IS, Ruby NF, Brooke S, et al. Sleep deprivation elevates plasma corticosterone levels in neonatal rats. Neurosci Lett. 2001;315:29-32.

262.Maelicke A, Coban T, Schrattenholz A, et al. Physostigmine and neuromuscular transmission. Ann N Y Acad Sci. 1993;681:140-54.

263.Aiello-Malmberg P, Bartolini A, Bartolini R, Galli A. Effects of morphine, physostigmine and raphe nuclei stimulation on 5-hydroxytryptamine release from the cerebral cortex of the cat. Br J Pharmacol. 1979;65:547-55.

264.Anden NE. Effects of oxotremorine and physostigmine on the turnover of dopamine in the corpus striatum and the limbic system. J Pharm Pharmacol. 1974;26:738-40.

265.Choi JY, Morris JC, Hsu CY. Aging and cerebrovascular disease. Neurol Clin. 1998;16:687-711.

266.Banks W, Kastin A. Aluminum increases permeability of the blood brain barrier to labeled DSIP and ß-endorphin: possible implications for senile and dialysis dementia. Lancet. 1983:1227-1229.

267.Sinton CM, Fitch TE, Petty F, Haley RW. Stressful manipulations that elevate corticosterone reduce blood brain barrier permeability to pyridostigmine in the rat. Toxicology and Applied Pharmacology. 2000;165:99-105.

268.Telang FW, Ding YS, Volkow ND, Molina PE, Gatley SJ. Pyridostigmine, a carbamate acetylcholinesterase AChE inhibitor and reactivator, is used prophylactically against chemical warfare agents. Nucl Med Biol. 1999;26:249-50.

269.Jones KH, Dechkovskaia AM, Herrick EA, Abdel-Rahman AA, Khan WA, Abou-Donia MB. Subchronic effects following a single sarin exposure on blood-brain and blood-testes barrier permeability, acetylcholinesterase, and acetylcholine receptors in the central nervous system of rat: a dose-response study. J Toxicol Environ Health A. 2000;61:695-707.

270.Lallement G, Foquin A, Baubichon D, Burckhart MF, Carpentier P, Canini F. Heat stress, even extreme, does not induce penetration of pyridostigmine into the brain of guinea pigs. Neurotoxicology. 1998;19:759-66.

271.Friedman A, Kaufer D, Shemer J, Hendler I, Soreq H, Tur-Kaspa I. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat Med. 1996;2:1382-5.

272.Tian H, Song X, Bressler J, Pruett S, Pope CN. Neither forced running nor forced swimming affect acute pyridostigmine toxicity or brain-regional cholinesterase inhibition in rats. Toxicology. 2002;176:39-50.

273.Cook WO, Beasley VR, Dahlem AM, Dellinger JA, Harlin KS, Carmichael WW. Comparison of effects of anatoxin-a(s) and paraoxon, physostigmine and pyridostigmine on mouse brain cholinesterase activity. Toxicon. 1988;26:750-3.

274.Lin J, Freeman JJ, Kosh JW. Antagonism of acute physostigmine and neostigmine toxicity in mice by hemicholinium-3. Res Commun Chem Pathol Pharmacol. 1987;56:137-40.

275.Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamazaki N. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol. 1985;56:247-51.

276.Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr. 1999;53:764-70.

277.Thorsteinsdottir B, Rafnsdottir S, Geirsson AJ, Sigurjonsson SV, Kjeld M. No difference in ubiquinone concentration of muscles and blood in fibromyalgia patients and healthy controls. Clin Exp Rheumatol. 1998;16:513-4.

278.Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res. 2002;30:195-9.

279.Sneed PA. Treatment of fibromyalgia with ubiquinone 10 and succinic acid. Official Gazette of the United States Patent and Trademark Office Patents. 2002;1255:No Pagination.

280.Krieger AC, Redeker NS. Obstructive sleep apnea syndrome: its relationship with hypertension. J Cardiovasc Nurs. 2002;17:1-11.

281.Blankfield RP, Zyzanski SJ. Bilateral leg edema, pulmonary hypertension, and obstructive sleep apnea: a cross-sectional study. J Fam Pract. 2002;51:561-4.

282.Yamakawa H, Shiomi T, Sasanabe R, et al. Pulmonary hypertension in patients with severe obstructive sleep apnea. Psychiatry Clin Neurosci. 2002;56:311-2.

283.Lee AG, Golnik K, Kardon R, Wall M, Eggenberger E, Yedavally S. Sleep apnea and intracranial hypertension in men. Ophthalmology. 2002;109:482-5.

284.Blankfield RP, Tapolyai AA, Zyzanski SJ. Left ventricular dysfunction, pulmonary hypertension, obesity, and sleep apnea. Sleep Breath. 2001;5:57-62.

285.Silverberg DS, Iaina A, Oksenberg A. Treating obstructive sleep apnea improves essential hypertension and quality of life. Am Fam Physician. 2002;65:229-36.

286.Chaska BW. Obstructive sleep apnea and essential hypertension--is there a link? Am Fam Physician. 2002;65:182, 185-6.

287.Alchanatis M, Tourkohoriti G, Kakouros S, Kosmas E, Podaras S, Jordanoglou JB. Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration. 2001;68:566-72.

288.Richert A, Ansarin K, Baran AS. Sleep apnea and hypertension: pathophysiologic mechanisms. Semin Nephrol. 2002;22:71-7.

289.Lavie P, Silverberg D, Oksenberg A, Hoffstein V. Obstructive sleep apnea and hypertension: from correlative to causative relationship. J Clin Hypertens (Greenwich). 2001;3:296-301.

290.von Kanel R, Le DT, Nelesen RA, Mills PJ, Ancoli-Israel S, Dimsdale JE. The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens. 2001;19:1445-51.

291.Sanders MH. Article reviewed: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. 2000;1:327-328.

292.Otsuka K. [Nasal CPAP treatment and hypertension and altered cardiovascular variability associated with obstructive sleep apnea (OSA)]. Nippon Rinsho. 2001;59:983-91.

293.Narkiewicz K, Somers VK. Obstructive sleep apnea as a cause of neurogenic hypertension. Curr Hypertens Rep. 1999;1:268-73.

294.Shiomi T, Guilleminault C, Sasanabe R, et al. Primary pulmonary hypertension with central sleep apnea: sudden death after bilevel positive airway pressure therapy. Jpn Circ J. 2000;64:723-6.

295.Hudgel DW. Beyond systemic hypertension: understanding cardiac dysfunction in obstructive sleep apnea. Respiration. 2000;67:360-1.

296.Salo TM, Jula AM, Piha JS, et al. Comparison of autonomic withdrawal in men with obstructive sleep apnea syndrome, systemic hypertension, and neither condition. Am J Cardiol. 2000;85:232-8.

297.Willis RA, Anthony M, Loop R, Llanes C, Folkers K. The effect of ethanol and/or food restriction on coenzyme Q in liver in rats. Mol Aspects Med. 1997;18 Suppl:S205-11.

298.Silvestre-Aillaud P, BenDahan D, Paquis-Fluckinger V, et al. Could coenzyme Q10 and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA? Diabetologia. 1995;38:1485-6.

299.Kucharska J, Braunova Z, Ulicna O, Zlatos L, Gvozdjakova A. Deficit of coenzyme Q in heart and liver mitochondria of rats with streptozotocin-induced diabetes. Physiol Res. 2000;49:411-8.

300.Liou CW, Huang CC, Lin TK, Tsai JL, Wei YH. Correction of pancreatic beta-cell dysfunction with coenzyme Q(10) in a patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome and diabetes mellitus. Eur Neurol. 2000;43:54-5.

301.Kishi T, Kishi H, Watanabe T, Folkers K. Bioenergetics in clinical medicine. XI. Studies on coenzyme Q and diabetes mellitus. J Med. 1976;7:307-21.

302.Iwasaki Y, Wakata N, Kinoshita M. Parkinsonism induced by pyridostigmine. Acta Neurol Scand. 1988;78:236.

303.Iwasaki Y, Kinoshita M, Wakata N. [A case report of pyridostigmine induced parkinsonism]. Rinsho Shinkeigaku. 1988;28:662-4.

304.Gothoni P, Lehtinen M, Fincke M. Drugs for Parkinson's disease reduce tremor induced by physostigmine. Naunyn Schmiedebergs Arch Pharmacol. 1983;323:205-10.

305.Friedrich MJ. Pesticide study aids Parkinson research. Jama. 1999;282:2200.

306.Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42:1328-35.

307.Ritz B, Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol. 2000;29:323-9.

308.Taylor MC, Le Couteur DG, Mellick GD, Board PG. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm. 2000;107:979-83.

309.Berger A. Parkinson's disease linked with pesticide. Bmj. 2000;321:1175A.

310.Adam D. Pesticide use linked to Parkinson's disease. Nature. 2000;408:125.

311.Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301-6.

312.Helmuth L. Neuroscience. Pesticide causes Parkinson's in rats. Science. 2000;290:1068.

313.Karen DJ, Li W, Harp PR, Gillette JS, Bloomquis JR. Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos. Neurotoxicology. 2001;22:811-7.

314.Ambrani LM, Van Woert MH. Modification of the tremorigenic activity of physostigmine. Br J Pharmacol. 1972;46:344-7.

315.Ambani LM, Van Woert MH, Bowers MB, Jr. Physostigmine effects on phenothiazine-induced extrapyramidal reactions. Arch Neurol. 1973;29:444-6.

316.Haley RW, Hom J, Roland PS, et al. Evaluation of neurologic function in Gulf War veterans. A blinded case-control study. Jama. 1997;277:223-30.

317.Hom J, Haley RW, Kurt TL. Neuropsychological correlates of Gulf War syndrome. Arch Clin Neuropsychol. 1997;12:531-544.

318.McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano). 2001;13:143-62.

319.Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. Jama. 1996;275:528-32.

320.Head injury linked to increased risk of Alzheimer's disease. FDA Consum. 2001;35:8.

321.Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology. 2000;55:1158-66.

322.SoRelle R. Head injuries linked to Alzheimer's disease. Circulation. 2000;102:E9036-7.

323.Sobel RK. Alzheimer's first blow. Head injuries raise risk. US News World Rep. 2000;129:54.

324.Norris FH, Tan Y, Fallat RJ, Elias L. Trial of oral physostigmine in amyotrophic lateral sclerosis. Clin Pharmacol Ther. 1993;54:680-2.

325.Aquilonius SM, Askmark H, Eckernas SA, et al. Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine. Acta Neurol Scand. 1986;73:628-32.

326.Backman SB, Stein RD, Blank DW, Collier B, Polosa C. Different properties of the bradycardia produced by neostigmine and edrophonium in the cat. Can J Anaesth. 1996;43:731-40.

327.Baraka A. Safe reversal. 2. Atropine-neostigmine mixture: an electrocardiographic study. Br J Anaesth. 1968;40:30-6.

328.Baraka A. Safe reversal. 1. Atropine followed by neostigmine. An electrocardiographic study. Br J Anaesth. 1968;40:27-9.

329.Beebe DS, Shumway SJ, Maddock R. Sinus arrest after intravenous neostigmine in two heart transplant recipients. Anesth Analg. 1994;78:779-82.

330.Bramich NJ, Brock JA, Hirst GD. Potentiation by neostigmine of responses to vagal nerve stimulation in the sinus venosus of the toad. Auton Neurosci. 2000;82:109-14.

331.Cavaliere F, Martinelli L, Rossi M, Zamparelli R, Gennari A, Schiavello R. [Effectiveness of low-dose neostigmine in the treatment of sinus tachycardia during aortocoronary bypass]. Minerva Anestesiol. 1993;59:361-5.

332.Constable PD, Muir WW, 3rd, Freeman L, Hoffsis GF, St Jean G, Welker FH. Atrial fibrillation associated with neostigmine administration in three cows. J Am Vet Med Assoc. 1990;196:329-32.

333.Dowdy EG. Effect of neostigmine on cardiac rhythm in digitalized dogs. Guest discussion. Anesth Analg. 1971;50:1088-9.

334.Fuchs-Buder T, Ziegenfuss T, Lysakowski K, Tassonyi E. Antagonism of vecuronium-induced neuromuscular block in patients pretreated with magnesium sulphate: dose-effect relationship of neostigmine. Br J Anaesth. 1999;82:61-5.

335.Eldor J, Frankel DZ. Use of low-dose neostigmine intravenously in the treatment of supraventricular tachycardia: an immediate bradycardic effect. Resuscitation. 1989;18:103-10.

336.Ivankovic AD, Ruggiero RP, el-Etr AA, Kaye MP. Effect of neostigmine on cardiac rhythm in digitalized dogs. Anesth Analg. 1971;50:1079-88.

337.Kadoya T, Seto A, Aoyama K, Takenaka I. Development of rapid atrial fibrillation with a wide QRS complex after neostigmine in a patient with intermittent Wolff-Parkinson-White syndrome. Br J Anaesth. 1999;83:815-8.

338.Kjellberg M, Tammisto T. Heart-rate changes after atropine and neostigmine given for the reversion of muscle paralysis. Acta Anaesthesiol Scand. 1970;14:203-10.

339.Klingenmaier CH, Bullard R, Thompson D, Watson R. Reversal of neuromuscular blockade with a mixture of neostigmine and glycopyrrolate. Anesth Analg. 1972;51:468-72.

340.Pratila MG, Pratilas V. A case of tachydysrhythmia. Refractory to propranolol and responsive to neostigmine. Anaesthesia. 1977;32:1017-9.

341.Raymond CW. Letter: Neostigmine methysulfate in the treatment of cardiac arryhthmia induced by perphenazine-amitriptyline. Can Med Assoc J. 1976;114:102-7.

342.Rosner V, Kepes ER, Foldes FF. The effects of atropine and neostigmine on heart rate and rhythm. Recommendation for their use to reverse residual neuromuscular block. Br J Anaesth. 1971;43:1066-74.

343.Schultheis LW, Balser JR, Calkins H, et al. High dose neostigmine treatment of malignant sinus tachycardia. Pacing Clin Electrophysiol. 1997;20:1369-72.

344.Tetzlaff JE, Choban MJ. Asystole following neostigmine administration during carotid sinus stimulation. J Clin Anesth. 1990;2:212-3.

345.Wetterslev J, Jarnvig I, Jorgensen LN, Olsen NV. Split-dose atropine versus glycopyrrolate with neostigmine for reversal of gallamine-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1991;35:398-401.

346.Bigger JT, Jr., Kantor SJ, Glassman AH, Perel JM. Is physostigmine effective for cardiac toxicity of tricyclic antidepressant drugs. Jama. 1977;237:1311.

347.Das PK, Bhattacharya SK. Studies on the effect of physostigmine on experimental cardiac arrhythmias in dogs. Br J Pharmacol. 1972;44:397-403.

348.Dysken MW, Janowsky DS. Dose-related physostigmine-induced ventricular arrhythmia: case report. J Clin Psychiatry. 1985;46:446-7.

349.Elonen E. Effect of beta-adrenoceptor blocking drugs, physostigmine, and atropine on the toxicity of doxepin in mice. Med Biol. 1975;53:231-7.

350.Goldberger AL, Curtis GP. Immediate effects of physostigmine on amitryptyline-induced QRS prolongation. J Toxicol Clin Toxicol. 1982;19:445-54.

351.James TN, Urthaler F, Lewis RK. Termination of "ventricular" arrhythmias from digoxin by selective production of complete atrioventricular block with physostigmine in the dog. J Pharmacol Exp Ther. 1979;211:561-70.

352.Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M. Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels. Am J Psychiatry. 1985;142:738-40.

353.Kulig K, Rumack BH. Physostigmine and asystole. Ann Emerg Med. 1981;10:228-20.

354.Maister AH. Atrial fibrillation following physostigmine. Can Anaesth Soc J. 1983;30:419-21.

355.Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9:588-90.

356.Schmidt W, Lang K. Life-threatening dysrhythmias in severe thioridazine poisoning treated with physostigmine and transient atrial pacing. Crit Care Med. 1997;25:1925-30.

357.Schulz M, Schmoldt A. Successful physostigmine treatment of acute dothiepin intoxication. Pharmazie. 1994;49:614.

358.Seitz R, Wehr M, Pallmert N. [Arrhythmias in poisoning with tricyclic antidepressive agents. Successful treatment with physostigmine and sodium]. Dtsch Med Wochenschr. 1982;107:1096-9.

359.Snyder BD, Blonde L, McWhirter WR. Reversal of amitriptyline intoxication by physostigmine. Jama. 1974;230:1433-4.

360.Tobis J, Das BN. Cardiac complications in amitriptyline poisoning. Successful treatment with physostigmine. Jama. 1976;235:1474-6.

361.Wright SP. Usefulness of physostigmine in imipramine poisoning. A dramatic response in a child resistant to other therapy. Clin Pediatr (Phila). 1976;15:1123-8.

362.Weisdorf D, Kramer J, Goldbarg A, Klawans HL. Physostigmine for cardiac and neurologic manifestations of phenothiazine poisoning. Clin Pharmacol Ther. 1978;24:663-7.

363.Dorner G, Staudt J, Wenzel J, Kvetnansky R, Murgas K. Further evidence of teratogenic effects apparently produced by neurotransmitters during brain differentiation. Endokrinologie. 1977;70:S326-330.

364.Dorner G, Hecht K, Hinz G. Teratopsychogenetic effects apparently produced by nonphysiological neurotransmitter concentrations during brain differentiation. Endokrinologie. 1976;68:1-5.

365.Dorner G, Hinz G. Apparent effects of neurotransmitters on sexual differentiation of the brain without mediation of sex hormones. Endokrinologie. 1978;71:S104-108.

366.Landauer W. Cholinomimetic teratogens: Studies with chicken embryos. Teratology. 1975;12:125-146.

367.Al-Shekhlee A, Robin N, Kaminski HJ. Pyridostigmine-induced microcephaly. Neurology. 2001;56:1606-7.

368.Cowan DN, DeFraites RF, Gray GC, Goldenbaum MB, Wishik SM. The risk of birth defects among children of Persian Gulf War veterans. N Engl J Med. 1997;336:1650-6.

369.Penman AD, Tarver RS, Currier MM. No evidence of increase in birth defects and health problems among children born to Persian Gulf War Veterans in Mississippi. Mil Med. 1996;161:1-6.

370.Araneta MR, Destiche DA, Schlangen KM, Merz RD, Forrester MB, Gray GC. Birth defects prevalence among infants of Persian Gulf War veterans born in Hawaii, 1989-1993. Teratology. 2000;62:195-204.

371.Doyle P, Roman E, Maconochie N. Birth defects among children of Persian Gulf War veterans. N Engl J Med. 1997;337:1175-6.

372.Zhou YX, Yan QJ, Ci YX, et al. Detection of the organophosphorus nerve agent sarin by a competitive inhibition enzyme immunoassay. Arch Toxicol. 1995;69:644-8.

372.5Kang H, Magee C, Mahan C, et al. Pregnancy outcomes among U.S. Gulf War veterans: a population-based survey of 30,000 veterans. Ann Epidemiol. 2001;11:504-11.

1